Related Experiment Videos
[Pulmonary disease induced by methotrexate]
L Gruberg1, A Livneh, J Rozenman
1Dept. of Medicine F, Chaim Sheba Medical Center, Tel Hashomer.
Abstract:
A 68-year-old man with rheumatoid arthritis developed methotrexate-induced lung disease. He presented with fever, cough, respiratory distress and pulmonary infiltrates, which were initially mistaken for pneumonia. Alertness to this rare and dangerous complication of methotrexate treatment will reduce possible damage and help maintain its place as a leading medication for rheumatoid arthritis.
Insights
Methotrexate can cause a rare lung disease in rheumatoid arthritis patients, presenting as pneumonia. Early recognition of this methotrexate-induced lung disease is crucial for patient safety and continued treatment.
Area of Science:
- Rheumatology
- Pulmonology
- Toxicology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- Methotrexate is a primary disease-modifying antirheumatic drug (DMARD) for RA.
- Methotrexate has potential pulmonary toxicity.
Observation:
- A 68-year-old male RA patient presented with fever, cough, and respiratory distress.
- Pulmonary infiltrates were observed on imaging.
- Initial diagnosis was pneumonia.
Findings:
- The patient was diagnosed with methotrexate-induced lung disease.
- This highlights a rare but serious adverse effect of methotrexate therapy.
- Symptoms mimicked common respiratory infections.
Implications:
- Increased clinical awareness of methotrexate-induced lung disease is essential.
- Prompt diagnosis and management can prevent severe complications.
- Maintaining methotrexate's efficacy in RA requires vigilant monitoring for toxicity.